On Dec. 14, 2016, Medigen Vaccine Biologics (MVC) amended an existing agreement with the National Institutes of Health (NIH) to expand dengue vaccine market territories from 17 countries to 26 countries in order to include Brunei, Cambodia, Laos, Myanmar, Papua New Guinea, and high dengue incidence areas like Sri Lanka, Bangladesh, Nepal and Bhutan.

VLP is self-assembling envelope or capsid protein mimicking the morphology of native virus without the infectious viral genome, making VLP non-infectious yet able to induce required immune response.